Bharat Biotech defends Covaxin's safety amid BHU study findings

The BHU study, conducted between January 2022 and August 2023, found that serious AESIs, including stroke and Guillain-Barre syndrome, were reported in 1 percent of the individuals. The study highlighted that nearly 50 percent of participants experienced infections during the follow-up period, predominantly viral upper respiratory tract infections.